Author

T. Shibuki

h-index 13 View on Semantic Scholar

We have 3 of 147 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy.

BACKGROUND Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated w...

T. Taira, Mitsuhito Sasaki, G. Igarashi et al. · International Journal of Cli... · 0 citations

Open access Aug 2026

Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible, and future prospective studies are warranted to refine NFF dosing strategies.

Y. Ueda, Hiroki Taguchi, Mototsugu Shimokawa et al. · Scientific Reports · 0 citations

Review Open access Jul 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...

T. Hashimoto, T. Shibuki, T. Fujisawa et al. · International Journal of Cli... · 0 citations